Nanobiotix (NASDAQ:NBTX) Rating Increased to Hold at UBS Group

Nanobiotix (NASDAQ:NBTX) was upgraded by stock analysts at UBS Group to a “hold” rating in a report issued on Monday,Zacks.com reports.

Nanobiotix Stock Performance

Nanobiotix stock opened at $3.95 on Monday. The firm’s 50-day moving average is $3.30 and its 200-day moving average is $4.15. Nanobiotix has a 1 year low of $2.76 and a 1 year high of $7.51.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. OLD Mission Capital LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth about $139,000. Geode Capital Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth about $29,000. Jane Street Group LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth about $73,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix in the 4th quarter worth about $39,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.